Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

On Friday, February 05, Zimmer Biomet Holdings (NYSE:ZBH) will release its latest earnings report. Benzinga's outlook for Zimmer Biomet Holdings is included in the following report.

Zimmer Biomet Holdings's Earnings: A Preview

STOCKHOLM, Jan. 21, 2021 /PRNewswire/ -- Today, Bactiguard-coated Zimmer Biomet orthopaedic trauma implants received European regulatory clearance and CE mark. Preparations for registering the implants in the U.S. market are also ongoing. "I am very pleased that the CE mark has been...

Bactiguard-coated Zimmer Biomet trauma implants receive European regulatory clearance

WARSAW, Ind., Jan. 19, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that Ellison (Ellie) M. Humphrey has been appointed to the newly created position of Chief Transformation Officer and will report...

Zimmer Biomet Appoints Ellison M. Humphrey as Chief Transformation Officer

WARSAW, Ind., Jan. 8, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Friday, February 5, 2021 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that...

Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2020 Financial Results

Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.

Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow

Owing to lack of clarity around the scope and duration of the coronavirus pandemic, Zimmer Biomet (ZBH) is unable to gauge the impact on its overall business in 2020.

Zimmer Biomet (ZBH) Shows Strong Recovery Amid COVID-19 Woes

WARSAW, Ind., Dec. 16, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2020....

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2020

WARSAW, Ind., Dec. 14, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the 39th Annual J.P....

Zimmer Biomet to Present at 39th Annual J.P. Morgan Healthcare Conference

Campbell Soup

Evo Payments

Hub Group

Marvell Technology

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Marvell and Campbell Soup.

Wall Street's top analysts like these stocks amid the stimulus stalemate

Zimmer Biomet's (ZBH) mymobility with Apple Watch platform aids in transforming virtual patient care via the latest partnership with HSS.

Zimmer Biomet (ZBH), HSS Partner to Advance Remote Patient Care

Let's see if Zimmer Biomet (ZBH) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Now Choose Zimmer Biomet (ZBH) Stock?

Alliance Data Systems

Choice Hotels Int.

TripAdvisor

The benefits of reopening post-pandemic have not yet been factored in for these four stocks relative to their earnings, according to UBS analysts.

UBS Says These 4 Pandemic-Thrashed Stocks Have Become Cheap Relative To Their Earnings

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Zimmer (ZBH) Up 7% Since Last Earnings Report: Can It Continue?

This latest development aligns with Zimmer Biomet's (ZBH) active portfolio management strategy and the ongoing transformation of business aimed at long-term growth.

Zimmer Biomet (ZBH) Boosts Portfolio With A&E Medical Buyout

LOS ANGELES--(BUSINESS WIRE)--Vance Street Capital LLC (“Vance Street”) is pleased to announce it has completed the sale of A&E Medical Corporation (“A&E Medical”) to Zimmer Biomet (NYSE: ZBH) (“Zimmer”), a global leader in musculoskeletal healthcare, for $250 million. The transaction marks the second exit out of Vance Street's Sophomore Fund. Founded in 1968 and headquartered in Farmingdale, New Jersey, A&E Medical is a leading designer and manufacturer of a comprehensive portfolio

Vance Street Capital Recognizes Successful Exit of A&E Medical Corporation to Zimmer Biomet

WARSAW, Ind., Dec. 1, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today officially launched the Zimmer Biomet Foundation. The Foundation is a philanthropic 501(c)(3) organization that further strengthens the...

Zimmer Biomet Foundation Launches, Supporting Diverse and Underserved Communities, STEM Education, Community Health and Disaster Relief

Zimmer Biomet has exited the 3rd quarter better than expected, with tailwinds in hips and knees globally to drive top-line growth in years to come. The ROSA and Persona Revision segments have performed well YTD, alongside ~10% growth in US hips, which shows the orthopaedics market has made a recovery.

Zimmer Biomet: Secure Play For Orthopaedics Exposure, +20% Upside

Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q3 2020 Results - Earnings Call Transcript

The company's recovery from the coronavirus pandemic was better than expected.

How Zimmer Biomet Zoomed Past Wall Street's Third-Quarter Estimates

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

Zimmer (ZBH) delivered earnings and revenue surprises of 72.38% and 12.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Beats Q3 Earnings and Revenue Estimates

  Shares of Zimmer Biomet Holdings (NYSE:ZBH) were unchanged after the company reported Q3 results.

Zimmer Biomet: Q3 Earnings Insights

WARSAW, Ind., Nov. 6, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2020. The Company reported third quarter net sales of $1.929 billion, an increase of 2.0% over the prior year period, and an...

Zimmer Biomet Announces Third Quarter 2020 Financial Results

WARSAW, Ind., Nov. 5, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced preliminary results from a prospective, randomized controlled clinical trial to evaluate the impact of mymobility® with Apple...

Zimmer Biomet Announces Preliminary Results from mymobility® Clinical Study at 2020 AAHKS Annual Meeting

HMS Hlds

Hill-Rom Hlds

Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how ZBH, HRC and HMS are poised ahead of their announcements.

News for Zimmer Biomet Hlds Stock (ZBH)